CMAJ • September 15, 2009; 181 (6-7). doi:10.1503/cmaj.109-3013.
© 2009 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silversides, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silversides, A.
Related Collections
Right arrow Regulation
Right arrow Doing research

Enzyme therapy for Fabry patients in jeopardy

Ann Silversides

CMAJ


Figure 135
View larger version (104K):
[in this window]
[in a new window]

  		Canadian Fabry Association President Ed Koning has "lots of questions." Image courtesy of Canadian Fabry Association